ICN Spinoff Ribapharm Sues in Patent Dispute
- Share via
Ribapharm Inc. sued Hoffman-LaRoche Inc. in the Netherlands and countersued in Switzerland, raising the stakes in a patent dispute over the Costa Mesa company’s flagship drug, ribavirin.
In a press release Tuesday, Ribapharm said Hoffman-LaRoche plans to sell a rival version of ribavirin in the Netherlands as a treatment for hepatitis C and has launched a similar effort in Switzerland.
Ribapharm, which was spun off from ICN Pharmaceuticals Inc. in April, has been facing increased pressure from companies seeking marketing approval for generic versions of ribavirin. Representatives for the companies weren’t available to provide details.
Hoffman-LaRoche is a unit of Roche Holding AG.
Ribapharm shares lost 45 cents Tuesday to close at $5.35 on the New York Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
